Stereotactic Radiation Therapy with Chemotherapy in the Management of Recurrent Medulloblastomas
Authors:
- Masamitsu AbeMAMasamitsu Abe
- Sunao TokumaruSTSunao Tokumaru
- Kazuo TabuchiKTKazuo Tabuchi
- Yoshihisa KidaYKYoshihisa Kida
- Masashi TakagiMTMasashi Takagi
- Junichi ImamuraJIJunichi Imamura
- 1 February 2006
- journal article
- research article
- Published by S. Karger AG in Pediatric Neurosurgery
- Vol. 42 (2) , 81-88
Abstract
Medulloblastomas are highly lethal tumors when they recur. Very few patients survive with conventional treatment. This report documents the preliminary study results of a treatment for recurrent medulloblastomas consisting of stereotactic radiation therapy (SRT) with chemotherapy. Four patients had local recurrence without apparent metastases and 8 patients had metastases with or without local recurrence. Twelve patients with 18 lesions underwent SRT as a single session (n = 8) or in a hypofractionated manner (n = 10) using a gamma knife or modified linear accelerator. All patients then received systemic chemotherapy. Five patients were treated with one to two sequential courses of high-dose chemotherapy with peripheral blood stem cell transplantation. The reduction in tumor size after SRT was often remarkable. Fourteen of 18 lesions treated disappeared 1–6 months after SRT. Two of 4 patients who had local recurrences without apparent metastasis at the time of SRT are alive without evidence of disease 70 and 72 months after SRT, respectively. In contrast, all 8 patients with metastasis had new lesions either in the spinal canal or on the surface of the brain outside the target area of SRT. Median progression-free survival and overall survival from the time of SRT were 9 and 19 months, respectively. The Kaplan-Meier estimates of PFS and overall survival at 3 years were 17 and 25%, respectively. One patient had brainstem edema after SRT causing bulbar palsy and quadriparesis. One patient died of toxicity of chemotherapy. Our experience suggests that local recurrence can be controlled by SRT with chemotherapy but survival of patients with metastases can not be improved effectively by SRT in conjunction with aggressive chemotherapy.Keywords
This publication has 22 references indexed in Scilit:
- Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 StudyJournal of Clinical Oncology, 2003
- Results of Three-dimensional Stereotactically-guided Radiotherapy in Recurrent MedulloblastomaJournal of Neuro-Oncology, 2002
- Radiosurgery in the management of pediatric brain tumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumorsBone Marrow Transplantation, 2000
- Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- The use of stereotactic radiosurgical boost in the treatment of medulloblastomasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Results of Radiosurgery in the Management of Recurrent and Residual MedulloblastomaPediatric Neurosurgery, 1995
- Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapyJournal of Neurosurgery, 1994
- Surveillance Scanning of Children with MedulloblastomaNew England Journal of Medicine, 1994
- An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK)Acta Neurochirurgica, 1988